Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 25 of 98, showing 5 Applications out of 488 total, starting on record 121, ending on 125

# Protocol No Study Title Investigator(s) & Site(s)

121.

ECCT/10/09/03   A0661201
    A0661201   AN OPEN LABEL, NON-COMPARATIVE STUDY TO EVALUATE PARASITOLOGICAL CLEARANCE RATES AND PHARMACOKINETICS OF AZITHROMYCIN AND CHLOROQUINE FOLLOWING ADMINISTRATION OF A FIXED DOSE COMBINATION OF AZITHROMYCIN AND CHLOROQUINE (AZCQ) IN ASYMPTOMATIC PREGNANT WOMEN WITH PLASMODIUMFALCIPARUM PARASITEMIA IN SUB-SAHARAN AFRICA   
Principal Investigator(s)
1. Joshua Kimani
Site(s) in Kenya
University of Nairobi Institute of Tropical and Infectious Diseases Siaya District Hospital
 
View

122.

ECCT/24/08/04   WHO A66045
    Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre, non-inferiority trial   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Machakos county hospital (Machakos county)
2. Pumwani maternity hospital (Nairobi City county)
3. Kiambu level 5 hospital (Kiambu county)
 
View

123.

ECCT/22/11/02   UNCPM 22120 5-FU Study
    UNCPM  22120: Safety of adjuvant, self-administered intravaginal 5-fluorouracil (5-FU) cream following cervical intraepithelial neoplasia grade 2 and 3 (CIN2/3) treatment among HIV-positive women in Kenya: A pilot study   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Chemtai Mungo
Site(s) in Kenya
Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH)
 
View

124.

ECCT/23/03/01   Micronutrient supplementation
    Optimizing nutrient supplementation among pregnant and reproductive age women in Kenya (Virutubisho)   
Principal Investigator(s)
1. DR. Martha Kaeni Mwangome
Site(s) in Kenya
KILIFI
 
View

125.

ECCT/21/06/05   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of ageand older   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR-PHRD THIKA PROJECT
 
View